The trademark was filed by WestVac Biopharma Co., Ltd., a corporation established under the laws of the People's Republic of China (the "Applicant"). The application was published for oppositions on March 8, 2022, and received one opposition filed on June 1, 2022 by Novartis AG on Likelihood of confusion. the opponent was represented by Nordemann Czychowski & Partner Rechtsanwältinnen und Rechtsanwälte mbB and proceedings were handled in English, and the oppositon was dismissed by the Euorpean Union Intellectual Property Office with decision issued June 1, 2022
The application was filed in English, and English was also language of all opposition proceedings (Spanish was selected as the second language).